DE69823520D1 - Noribogain zur behandlung von schmerzen und drogenabhängigkeit - Google Patents

Noribogain zur behandlung von schmerzen und drogenabhängigkeit

Info

Publication number
DE69823520D1
DE69823520D1 DE69823520T DE69823520T DE69823520D1 DE 69823520 D1 DE69823520 D1 DE 69823520D1 DE 69823520 T DE69823520 T DE 69823520T DE 69823520 T DE69823520 T DE 69823520T DE 69823520 D1 DE69823520 D1 DE 69823520D1
Authority
DE
Germany
Prior art keywords
pain
treatment
noribogain
drug addiction
noribogaine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69823520T
Other languages
English (en)
Other versions
DE69823520T2 (de
Inventor
C Mash
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novoneuron Inc
Original Assignee
Novoneuron Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novoneuron Inc filed Critical Novoneuron Inc
Publication of DE69823520D1 publication Critical patent/DE69823520D1/de
Application granted granted Critical
Publication of DE69823520T2 publication Critical patent/DE69823520T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Addiction (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
DE69823520T 1997-09-04 1998-09-03 Noribogain zur behandlung von schmerzen und drogenabhängigkeit Expired - Lifetime DE69823520T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5792197P 1997-09-04 1997-09-04
US57921P 1997-09-04
PCT/US1998/018284 WO1999011250A2 (en) 1997-09-04 1998-09-03 Noribogaine in the treatment of pain and drug addiction

Publications (2)

Publication Number Publication Date
DE69823520D1 true DE69823520D1 (de) 2004-06-03
DE69823520T2 DE69823520T2 (de) 2005-05-12

Family

ID=22013572

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69823520T Expired - Lifetime DE69823520T2 (de) 1997-09-04 1998-09-03 Noribogain zur behandlung von schmerzen und drogenabhängigkeit

Country Status (9)

Country Link
US (6) US7754710B2 (de)
EP (4) EP2246058A1 (de)
AT (2) ATE265213T1 (de)
AU (1) AU754088B2 (de)
CA (1) CA2302754C (de)
DE (1) DE69823520T2 (de)
ES (3) ES2224430T3 (de)
IL (2) IL134796A0 (de)
WO (1) WO1999011250A2 (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001052851A1 (en) * 2000-01-22 2001-07-26 Albert Shulman Methods for the treatment of substance abuse
CN1525851A (zh) 2001-05-11 2004-09-01 ������ҩ�����޹�˾ 抗滥用阿片样物质控释剂型
AU2002303718B2 (en) * 2001-05-11 2008-02-28 Endo Pharmaceuticals, Inc. Abuse-resistant opioid dosage form
DK2425824T5 (en) 2002-04-05 2018-02-12 Mundipharma As Pharmaceutical preparation containing oxycodone and naloxone
EP1702558A1 (de) 2005-02-28 2006-09-20 Euro-Celtique S.A. Verfahren und Vorrichtung zur Darmtätigkeitserfassung
WO2010103039A1 (en) 2009-03-10 2010-09-16 Euro-Celtique S.A. Immediate release pharmaceutical compositions comprising oxycodone and naloxone
US8362007B1 (en) * 2010-05-11 2013-01-29 Demerx, Inc. Substituted noribogaine
US9394294B2 (en) 2010-05-11 2016-07-19 Demerx, Inc. Methods and compositions for preparing and purifying noribogaine
US8765737B1 (en) 2010-05-11 2014-07-01 Demerx, Inc. Methods and compositions for preparing and purifying noribogaine
US9586954B2 (en) 2010-06-22 2017-03-07 Demerx, Inc. N-substituted noribogaine prodrugs
US8741891B1 (en) 2010-06-22 2014-06-03 Demerx, Inc. N-substituted noribogaine prodrugs
US8802832B2 (en) 2010-06-22 2014-08-12 Demerx, Inc. Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier
US8637648B1 (en) 2010-06-22 2014-01-28 Demerx, Inc. Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier
US9358237B2 (en) 2010-07-23 2016-06-07 Demerx, Inc. Noribogaine compositions
EP2481740B1 (de) * 2011-01-26 2015-11-04 DemeRx, Inc. Verfahren und Zusammensetzungen zur Herstellung von Noribogain aus Voacangin
US8742096B2 (en) * 2011-03-28 2014-06-03 Demerx, Inc. Methods and compositions for preparing noribogaine from voacangine
US9617274B1 (en) 2011-08-26 2017-04-11 Demerx, Inc. Synthetic noribogaine
US9040520B2 (en) 2011-09-15 2015-05-26 Demerx, Inc. Noribogaine salt ansolvates
IN2014CN04160A (de) * 2011-12-08 2015-07-17 Demerx Inc
WO2013085849A2 (en) * 2011-12-09 2013-06-13 Demerx, Inc. Sulfate esters of noribogaine
WO2013085922A1 (en) * 2011-12-09 2013-06-13 Demerx, Inc. Phosphate esters of noribogaine
US8877921B2 (en) 2012-01-25 2014-11-04 Demerx, Inc. Synthetic voacangine
US9150584B2 (en) 2012-01-25 2015-10-06 Demerx, Inc. Indole and benzofuran fused isoquinuclidene derivatives and processes for preparing them
JP2016508979A (ja) * 2012-12-20 2016-03-24 デメレックス， インコーポレイテッド 置換ノルイボガイン
US9045481B2 (en) 2012-12-20 2015-06-02 Demerx, Inc. Substituted noribogaine
US8940728B2 (en) 2012-12-20 2015-01-27 Demerx, Inc. Substituted noribogaine
WO2014143201A1 (en) * 2013-03-15 2014-09-18 Demerx, Inc. Method for noribogaine treatment of addiction in patients on methadone
AU2014295042B2 (en) 2013-07-23 2017-03-30 Mundipharma Pty Limited A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
CA2875384A1 (en) 2013-12-20 2015-06-20 AntiOP, Inc. Intranasal naloxone compositions and methods of making and using same
AU2014383143A1 (en) * 2014-02-18 2016-09-29 Demerx, Inc. Methods for acute and long-term treatment of drug addiction
CA3221251A1 (en) * 2014-02-18 2015-08-27 Demerx, Inc. Therapeutic methods employing noribogaine and related compounds
US9345711B2 (en) * 2014-02-18 2016-05-24 Demerx, Inc. Methods for acute and long-term treatment of drug addiction
US9561232B2 (en) 2014-02-18 2017-02-07 Demerx, Inc. Low dose noribogaine for treating nicotine addiction and preventing relapse of nicotine use
US20150246055A1 (en) * 2014-03-03 2015-09-03 Demerx, Inc. Methods for acute and long-term treatment of opioid and opioid-like drug addiction
US20150258111A1 (en) * 2014-03-13 2015-09-17 Demerx, Inc. Methods and compositions for reducing tolerance to opioid analgesics using ibogaine and derivatives thereof
US9591978B2 (en) 2014-03-13 2017-03-14 Demerx, Inc. Methods and compositions for pre-screening patients for treatment with noribogaine
WO2015142346A1 (en) * 2014-03-20 2015-09-24 Demerx, Inc. Methods and compositions for preparing and purifying noribogaine
WO2015195673A2 (en) 2014-06-18 2015-12-23 Demerx, Inc. Halogenated indole and benzofuran derivatives of isoquinuclidene and processes for preparing them
US9549935B2 (en) 2014-07-14 2017-01-24 Demerx, Inc. Methods and compositions for treating migraines using noribogaine
US9592239B2 (en) 2014-09-12 2017-03-14 Demerx, Inc. Methods and compositions for ibogaine treatment of impulse control disorder, anxiety-related disorders, violence and/or anger, or regulating food intake
PT3223906T (pt) * 2014-11-26 2021-05-05 Demerx Inc Métodos e composições para potencializar a ação de analgésicos de opioides usando alcaloides de iboga
WO2016183244A1 (en) * 2015-05-11 2016-11-17 Demerx, Inc. Methods for treatment of opioid dependency and withdrawal using noribogaine
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
EP3955936A1 (de) 2019-04-17 2022-02-23 COMPASS Pathfinder Limited Behandlung von depression und anderen verschiedenen störungen mit psilocybin

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB841697A (en) * 1956-03-22 1960-07-20 Ciba Ltd Analgesic compositions
GB924042A (en) 1959-03-05 1963-04-18 Geigy Ag J R Process for the decarboxylation of alkyl esters of unsaturated, nitrogen-containing carboxylic acids
US3639408A (en) 1967-06-03 1972-02-01 Shionogi & Co Process for the preparation of isoquinuclidine derivatives
US3516989A (en) 1967-10-02 1970-06-23 American Home Prod Intermediates for total synthesis of iboga alkaloids and means of preparation
FR7131M (de) 1968-01-31 1969-07-21
US3557126A (en) 1969-08-14 1971-01-19 American Home Prod Derivatives of iboga alkaloids
US3574220A (en) 1969-08-14 1971-04-06 American Home Prod 1,7-methano-1h-1-benzazepin-5(4h)-ones
CA982478A (en) 1971-04-12 1976-01-27 Jerome Berk Orally administered drug composition for therapy in the treatment of narcotic drug addiction
US4375414A (en) 1971-05-20 1983-03-01 Meir Strahilevitz Immunological methods for removing species from the blood circulatory system and devices therefor
US3715361A (en) * 1971-10-08 1973-02-06 American Cyanamid Co Acyl derivatives of 10-methoxyibogamine
US3875011A (en) 1972-11-06 1975-04-01 Syva Co Enzyme immunoassays with glucose-6-phosphate dehydrogenase
US4272541A (en) 1978-06-02 1981-06-09 Miles Laboratories, Inc. 7,8 and 7-8 Substituted 4,5α-epoxymorphinan-6-one compounds, and methods of treating pain and drug dependence with them
US4464378A (en) 1981-04-28 1984-08-07 University Of Kentucky Research Foundation Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
CA1188989A (en) 1981-05-21 1985-06-18 Richard R. Scherschlicht Nonapeptide for the treatment of drug withdrawal symptoms
US4604365A (en) 1981-06-02 1986-08-05 Electro-Nucleonics, Inc. Immunoprecipitation assay
US4462941A (en) 1982-06-10 1984-07-31 The Regents Of The University Of California Dynorphin amide analogs
JPS59208119A (ja) * 1983-05-13 1984-11-26 Sankei Giken Kogyo Kk 触媒コンバ−タ
US4499096A (en) 1983-11-18 1985-02-12 Lotsof Howard S Rapid method for interrupting the narcotic addiction syndrome
US5266574A (en) * 1984-04-09 1993-11-30 Ian S. Zagon Growth regulation and related applications of opioid antagonists
US4626539A (en) 1984-08-10 1986-12-02 E. I. Dupont De Nemours And Company Trandermal delivery of opioids
US4573995A (en) * 1984-10-09 1986-03-04 Alza Corporation Transdermal therapeutic systems for the administration of naloxone, naltrexone and nalbuphine
GB8430346D0 (en) 1984-11-30 1985-01-09 Reckitt & Colmann Prod Ltd Analgesic compositions
ATE95430T1 (de) * 1984-12-22 1993-10-15 Sanol Arznei Schwarz Gmbh Wirkstoffpflaster.
US4806341A (en) 1985-02-25 1989-02-21 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration
US4587243A (en) 1985-07-15 1986-05-06 Lotsof Howard S Rapid method for interrupting the cocaine and amphetamine abuse syndrome
US5316759A (en) 1986-03-17 1994-05-31 Robert J. Schaap Agonist-antagonist combination to reduce the use of nicotine and other drugs
GB8625941D0 (en) * 1986-10-30 1986-12-03 Sandoz Ltd Substituted alpha-amino acids
US4857523A (en) 1988-07-18 1989-08-15 Nda International, Inc. Rapid method for attenuating the alcohol dependency syndrome
US5629307A (en) 1989-10-20 1997-05-13 Olney; John W. Use of ibogaine in reducing excitotoxic brain damage
US5075341A (en) 1989-12-01 1991-12-24 The Mclean Hospital Corporation Treatment for cocaine abuse
DE4010079A1 (de) 1990-03-29 1991-10-02 Lohmann Therapie Syst Lts Pharmazeutische formulierung zur behandlung des alkoholismus
US5026697A (en) 1990-05-30 1991-06-25 Nda International, Inc. Rapid method for interrupting or attenuating the nicotine/tobacco dependency syndrome
US5152994A (en) 1990-05-31 1992-10-06 Lotsof Howard S Rapid method for interrupting or attenuating poly-drug dependency syndromes
US5283247A (en) 1991-02-06 1994-02-01 Research Corporation Technologies, Inc. Anticonvulsant substituted quinazolones
US5149538A (en) 1991-06-14 1992-09-22 Warner-Lambert Company Misuse-resistive transdermal opioid dosage form
US5290784A (en) 1991-07-18 1994-03-01 Yueqian Qu Aconitane derivatives used as a medication to treat addiction
HU219476B (hu) 1992-04-10 2001-04-28 Merrell Dow Pharmaceuticals Inc. Eljárás valamely 2'-halo-metilidén-származékot és S-fázisú vagy M-fázisú specifikus daganatellenes szert tartalmazó gyógyszerkészítmények előállítására
EP0652765A4 (de) 1992-06-12 1997-04-09 Des Tyr Dynorphin Partnership Des-tyr dynorphinanaloge.
US5256669A (en) * 1992-08-07 1993-10-26 Aminotek Sciences, Inc. Methods and compositions for treating acute or chronic pain and drug addiction
US5580876A (en) 1992-09-21 1996-12-03 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
CA2145207A1 (en) 1992-09-21 1994-03-22 Bo-Yi Qin Methods for identifying and using low/non-addictive opioid analgesics
CN1042895C (zh) 1992-09-23 1999-04-14 曲曰谦 治疗吸毒者戒断综合症及脱瘾的药物组合物
AU4066693A (en) 1992-12-23 1994-07-19 Bernhard Hugemann Compacted drug body for use in the mechanical generation of inhalable active-substance particles
US5865444A (en) * 1994-03-21 1999-02-02 Deere & Company Body leveling suspension including a pivoting arrangement
JP2819236B2 (ja) 1994-05-06 1998-10-30 日東電工株式会社 経皮吸収製剤
US5552406A (en) 1994-06-17 1996-09-03 The Mclean Hospital Corporation Method for treating pain and brain perfusion abnormalities using mixed opioid agonist-antagonists
FR2721945B1 (fr) 1994-07-04 1996-10-18 David Fabrice Accroissement genique, un procede d'amplicication genique isotherme et ses applications
MX9701430A (es) 1994-07-25 1997-12-31 Nda Int Inc Un metodo de tratamiento de dependencia quimica en mamiferos y una composicion para el mismo.
US5591738A (en) * 1994-10-14 1997-01-07 Nda International, Inc. Method of treating chemical dependency using β-carboline alkaloids, derivatives and salts thereof
US5760044A (en) 1996-05-16 1998-06-02 Archer; Sydney Method for treating cocaine and amphetamine dependency
US6451806B2 (en) * 1999-09-29 2002-09-17 Adolor Corporation Methods and compositions involving opioids and antagonists thereof
US6864271B2 (en) * 2002-11-12 2005-03-08 The Foundation For The Lsu Health Sciences Center Synergistic combinations including N-acylated 4-hydroxyphenylamine derivatives
AU2004200486B2 (en) 2003-02-12 2007-06-07 Samsung Electronics Co., Ltd. Complex wireless service apparatus using wired and wireless communication systems and method thereof
US6806291B1 (en) * 2003-10-09 2004-10-19 The Foundation For The Lsu Health Sciences Center Analgesic compounds, their synthesis and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
US20100311725A1 (en) 2010-12-09
CA2302754C (en) 2011-11-08
CA2302754A1 (en) 1999-03-11
ES2395268T3 (es) 2013-02-11
ES2435722T3 (es) 2013-12-23
EP2338494B1 (de) 2013-07-10
US20100311722A1 (en) 2010-12-09
ES2224430T3 (es) 2005-03-01
IL134796A0 (en) 2001-04-30
US20100311724A1 (en) 2010-12-09
US20100311723A1 (en) 2010-12-09
AU9217498A (en) 1999-03-22
WO1999011250A3 (en) 1999-08-05
EP2338494A1 (de) 2011-06-29
ATE510542T1 (de) 2011-06-15
EP1327447B1 (de) 2011-05-25
WO1999011250A2 (en) 1999-03-11
US20120083485A1 (en) 2012-04-05
ATE265213T1 (de) 2004-05-15
EP1009407B1 (de) 2004-04-28
AU754088B2 (en) 2002-11-07
US7754710B2 (en) 2010-07-13
EP2246058A1 (de) 2010-11-03
US20070185085A1 (en) 2007-08-09
EP1327447A1 (de) 2003-07-16
EP1009407A2 (de) 2000-06-21
US8178524B2 (en) 2012-05-15
IL134796A (en) 2008-11-26
DE69823520T2 (de) 2005-05-12

Similar Documents

Publication Publication Date Title
DE69823520D1 (de) Noribogain zur behandlung von schmerzen und drogenabhängigkeit
ATE399553T1 (de) Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
DE60239612D1 (de) Monodisperse mischungen und verfahren zur behandlung von diabetes
DE69428523D1 (de) Verfahren zur behandlung von gemüts- oder geisteskrankheiten und von gemüts- oder geisteskrankheiten, die von anfällen begleitet sind
NO20060913L (no) Behandling av avhengighetsabstinens
NZ515301A (en) Pharmaceutical product comprising the active substance diamorphine, and its use in a process for treating opiate addiction
AU2003268144A8 (en) Transdermal dosage form comprising an active agent and a salt and free-baseform of an antagonist
DE60234183D1 (de) Verwendung von methylnaltrexon zur behandlung von immunsuppression
WO2001093852A3 (en) Method of treating pain using nalbuphine and opioid antagonists
ATE154758T1 (de) Levobupivacain nützlich zur behandlung von chronischen schmerzen
ATE394097T1 (de) Verfahren zur verabreichung von buprenorphin zur behandlung von depression
HRP20080146T3 (en) Preoperative treatment of post operative pain
ATE214272T1 (de) Topische verwendung von kappa- opioidrezeptoragonisten zur behandlung von augenschmerz
ATE453402T1 (de) Verwendung von serp-1 in kombination mit einem immunosuppressor zur behandlung von arthritis
ATE281841T1 (de) Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen
ATE262362T1 (de) Verwendung von cyamemazin zur behandlung von entwöhnungserscheinungen der benzodiazepinbehandlung
DE69733321D1 (de) Olanzapine zur behandlung von drogenmissbrauch
Gwon et al. Effects of Electro-Acupuncture (EA) and Scalp-Acupuncture (SA) on the Plasma Cortisol in neck, shoulder and upper limb pain
UA31157A (uk) Спосіб лікування опіатної наркоманії
UA33439A (uk) Спосіб інтенсивного лікування шизофренії

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: STROHSCHAENK UND KOLLEGEN, 85521 OTTOBRUNN